New guidelines recommend using the full approved doses of immunotherapy and targeted therapies for patients with cancer and obesity.
The combination of lenvatinib and pembrolizumab improved health-related quality of life.
Adding telaglenastat to cabozantinib does not significantly prolong PFS compared with placebo plus cabozantinib in patients with mRCC whose disease progressed after 1 or 2 prior lines of systemic therapy.
Pembrolizumab plus axitinib improved progression-free and overall survival.
In the randomized phase 3 KEYNOTE-564 trial, pembrolizumab treatment after nephrectomy for clear cell RCC was associated with a 32% decreased risk of cancer recurrence or death compared with placebo.
Black cancer patients were 44% less likely than White patients to enroll in a portal that provides access to electronic health records.
A meta-analysis of phase 3 randomized control trials sought to identify the TRAEs associated with 7 therapeutic regimens for the treatment of mRCC.
A review of retrospective data sought to better understand the relationship between obesity and survival in renal cell carcinoma.
For real-world patients with mRCC, active surveillance may be a worthwhile alternative to immediate systemic therapy.
Local surgery or ablation may be most appropriate for patients with a solitary site of locoregional recurrence following definitive surgery for clinically localized renal cell carcinoma, according to investigators.
Investigators report findings from the phase 3 CLEAR trial that assessed outcomes with pembrolizumab plus lenvatinib, lenvatinib plus everolimus, or sunitinib in treatment-naive patients with advanced renal cell carcinoma.
A study was conducted to assess factors contributing to response to nivolumab treatment for advanced clear cell renal cell carcinoma.
The approval was based on data from a phase 3 TIVO-3 study that compared tivozanib to sorafenib in adults with relapsed or refractory advanced RCC after 2 or more prior systemic therapies.
Combination therapy superior with respect to progression-free, overall survival and overall response for first-line treatment of advanced RCC.
New study data offer insight on the mechanisms of angiotensin converting enzyme 2 (ACE2) in clear cell renal cell carcinoma (ccRCC).
Researchers sought to determine accessibility and use of palliative care among patients with advanced renal cell carcinoma.
Todd Bauer, MD, presents updated data from a phase 1/2 study of the oral hypoxia-inducible factor-2α (HIF-2α) inhibitor belzutifan.
Investigators studied whether sexual orientation affects screening for prevalent gender-specific cancers including prostate, breast, and cervical cancer.
Lythgoe et al studied patterns of race reporting in genitourinary (GU) cancer trials.
A retrospective analysis evaluated the incidence of ONJ in patients who received VEGF-TKIs or immune-oncology therapy for mRCC and bone-targeted therapies for bone metastases.